Differences in Antiretroviral Adherence Behaviors, Treatment Success, and Eligibility for Long-Acting Injectable Treatment between Patients Who Acquired HIV in Childhood vs. Those Who Acquired It in Adolescence/Early Adulthood

Anthony Marcellin 1,*, Valérie Martel-Laferrière 2,*, Anne-Geneviève Genest 3, Bertrand Lebouché 4,*, and Suzanne Marcotte 5,*

1 Faculty of Pharmacy, Aix-Marseille University, 13284 Marseille, France
2 Division of Microbiology and Infectious Diseases and Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, QC H2X0C1, Canada
3 Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park, QC J4V2H1, Canada
4 McGill University Health Centre (MUHC), Montréal, QC H4A3J1, Canada
5 Department of Pharmacy, Centre Hospitalier de l’Université de Montréal (CHUM), Montréal, QC H2X0C1, Canada

* Correspondence: anthony.marcellin3@gmail.com (A.M.); valerie.martel-laferriere.med@ssss.gouv.qc.ca (V.M.-L.); bertrand.lebouche@mcgill.ca (B.L.); suzanne.marcotte.chum@ssss.gouv.qc.ca (S.M.)

Abstract: This study investigates the impact of the age at which HIV was acquired on adherence. There was no difference in adherence between patients who acquired HIV in childhood vs. those who acquired it in adolescence/early adulthood (83% vs. 90%; \( p = 0.24 \)), but achievement of virological/immunological efficacy (78.8% vs. 93.5%, \( p = 0.02 \)) was less likely in patients who had acquired HIV in childhood. On the basis of resistance, patients who acquired HIV in adolescence/early adulthood tended to be more eligible for cabotegravir/rilpivirine treatment (90.3% vs. 80.3%; \( p = 0.11 \)).

Keywords: HIV; compliance; viral resistances; long-acting injectable antiretrovirals; youth

1. Introduction

Despite simpler and more tolerable regimens for treating HIV infection, suboptimal adherence remains common, particularly among young patients [1–7]. Young adults may face multiple challenges, such as identity issues, unveiling, lack of a family model, and thinking in terms of short-term benefits [8,9]. This study aims to compare adherence depending on the timing of infection acquisition, i.e., infancy/childhood versus adolescence/early adulthood, to explore the causes of non-adherence and to compare the two groups in terms of the HIV viral load, resistance to antiretroviral therapies, and eligibility for injectable cabotegravir–rilpivirine.

2. Materials and Methods

This study included a retrospective chart review and a survey in order to identify factors of non-adherence from the point of view of the healthcare team, and that of the patient, respectively.

2.1. Retrospective Study

This study included all patients infected with HIV younger than 25 years of age, currently aged between 18 and 30 (as of 1 May 2021), and seen in three Canadian clinics in the Montreal area (Centre Hospitalier de l’Université de Montréal (CHUM), McGill University Health Center (MUHC), and Charles LeMoyne Hospital (CLMH)). Patients for
whom no antiretroviral had been prescribed, or lacking minimal biological data in the medical file (HIV viral load and CD4 count) were excluded. The population was divided into two groups: patients with HIV diagnosed before the age of 10 (group 1), and patients diagnosed with HIV between the ages of 10 and 25 (group 2). Data were collected between 1 June 2021 and 27 August 2021, in Montreal. For the cross-sectional study, patients already receiving long-acting injectable antiretrovirals were excluded.

Data collected included adherence to antiretrovirals as systematically reported in the health care providers’ notes, potential viral resistance determined by genotype testing, and the complexity of the antiretroviral regimen. Poor/insufficient adherence was defined as omitting to take 20% or more of monthly doses, based on the minimum threshold of 80% required for therapeutic adherence in the context of antiretrovirals [6]. We defined good immunological and virological efficacy when the viral load was below 200 copies per ml or undetectable, and when the CD4+ T-lymphocytes count was above 200 cells per mm³. Eligibility for cabotegravir/rilpivirine was determined on the basis of the absence of specific mutations, i.e., E138A/G/K/Q/R, K101P/E/Q, V179L, H221Y, F227C, M230I/L, and Y181C/I/V for rilpivirine and S147G, R263K, H51Y, and S153F/Y for cabotegravir, as defined by the Stanford University HIV Drug Resistance Database, and International Antiviral Society-USA [10,11]. In the absence of genotype, patients were assumed to be free of mutations of interest.

2.2. Survey

For the cross-sectional study, all patients included in the retrospective chart review were invited, by email or letter, to complete an electronic questionnaire in order to identify self-reported causes of non-adherence to antiretrovirals, except for those already on injectable treatment. With the author’s permission, we used the Godin questionnaire, in English and French, which is validated for antiretroviral therapy (ART) adherence in the Canadian population [12]. It is a brief and simple self-reporting questionnaire evaluating the number of antiretroviral pills missed in the previous 7 days, social activities in the past week (leisure activities, going to bars, restaurants, etc.), and impact on ART adherence (Appendix A). In addition, we included a visual analog scale and some questions to explore the causes of non-adherence and the patient’s interest in a long-acting injectable treatment. The RedCap® software (survey function) was used to collect the data. An HTML link to the questionnaire and a QR-Code with the same function were included in the letter or email inviting participation in the study. To encourage participation, for those who used email for communication, the email was sent 3 times at 2-week intervals. For the others, a letter inviting participation was sent twice by postal mail. About half of the patients were also invited by phone to complete the questionnaire, as this was permitted by the ethics committee at only one of the three participating sites. Informed consent was signed electronically by answering the first question. Participants had the opportunity to enter a draw for a CAD 100 gift card. This study received multicentric approval by the CHUM institutional review and research ethics board.

2.3. Statistical Analysis

Groups were described using means, with a 95% confidence interval (95% CI), and numbers, with proportions, for continuous and categorical variables, respectively. The Mann–Whitney U test was used for a comparative analysis of continuous variables, while chi-square tests and Fisher’s exact test were used for a comparative analysis of categorical variables. Analyses were performed using SPSS Statistics v.26 (IBM Corporation, Armonk, NY, USA).

3. Results

Out of 148 patients screened, 128 were included (CHUM = 29, MUHC = 92, and CLMH = 7). The reasons for exclusions were: diagnosis of HIV infection over the age of 25 (n = 14), inability to determine the date of diagnosis (n = 4), insufficient biological data in
the medical file \((n = 1)\), and absence of a prescribed antiretroviral \((n = 1)\). In all, 66 patients were included in group 1 (HIV diagnosed before the age of 10) and 62 in group 2 (patients diagnosed between the ages of 10 and 25) (Table 1).

Table 1. Demographics.

|                     | Dx before Age 10 \((n = 66)\) | Dx between 10 and 25 \((n = 62)\) |
|---------------------|-------------------------------|----------------------------------|
| Age                 | 23.97 \(\pm 3.13\)           | 26.50 \(\pm 2.24\)              |
| Range               | 17–29                         | 21–29                           |
| Presumed duration of infection | 22.60 \(\pm 5.18\)           | 5.12 \(\pm 3.31\)              |
| Gender              |                               |                                  |
| Female              | 35 \((53\%)\)                | 16 \((26\%)\)                   |
| Male                | 30 \((45\%)\)                | 44 \((71\%)\)                   |
| Genderfluid, transgender, non-binary | 1 \((2\%)\)            | 2 \((3\%)\)                      |
| Transmission mode   |                               |                                  |
| Ante- or perinatal  | 63 \((95.5\%)\)              | 0 \((0.0\%)\)                   |
| Sexual transmission | 0 \((0.0\%)\)                | 55 \((88.7\%)\)                |
| Injection drug use (IDU) | 0 \((0.0\%)\)           | 0 \((0.0\%)\)                   |
| Other, unknown      | 3 \((4.5\%)\)                | 7 \((11.3\%)\)                  |
| Regimen complexity  |                               |                                  |
| One pill, once a day (Single-Tablet Regimens) | 44 \((66.7\%)\)         | 58 \((93.5\%)\)                 |
| More than one pill, once a day | 18 \((27.3\%)\)        | 1 \((1.6\%)\)                    |
| Other regimen       | 4 \((6.1\%)\)                | 3 \((4.8\%)\)                   |

Dx, Diagnosed; SD, Standard-Deviation.

3.1. Retrospective Study

HIV transmission was mainly perinatal in group 1 \((95.5\%)\) and sexual in group 2 \((88.7\%)\). No transmission through injection drug use was noted in the charts, but 10 patients had acquired HIV by another or unknown route.

The two most commonly used regimens were tenofovir alafenamide/emtricitabine/bictegravir \((44\%\); 34\%\) and lamivudine/abacavir/dolutegravir \((34\%; 27\%)\). Adherence to treatment did not statistically differ between the groups \((\text{group } 1: 83\% \text{ vs. group } 2: 90\%; \(p = 0.24\)), but there were significantly fewer patients with good immunological and virological ART efficacy in group 1 compared to patients in group 2 \((78.8\% \text{ vs. } 93.5\%; \(p = 0.02\)). Most patients in group 2 \((93.5\%)\) reached virological suppression against only 81.8\% in the group 1 \((p = 0.05)\). Overall, independently of their group, patients with poor or insufficient adherence were more at risk of poor or incomplete immuno-virological efficacy \((76.5\% \text{ vs. } 4.5\%; \(p < 0.001\)).

In terms of viral mutations, we observed significantly higher drug resistance in group 1 \((\text{mean number of pharmacological classes impacted by resistance mutations: } 1.17 \text{ (95\% CI: 0.81–1.52) vs. } 0.38 \text{ (95\% CI: 0.19–0.56); } p = 0.002)\). Nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) resistance \((47.9\% \text{ vs. } 2.5\%; \(p = 0.001\)) were more likely in group 1 compared to group 2.

Regarding the eligibility of patients for long-acting injectable cabotegravir/rilpivirine on the basis of resistance, there seemed to be more eligible patients in group 2, but this relation was not statistically significant \((80.3\% \text{ vs. } 90.3\%; \(p = 0.11\)). Nine patients \((\text{six in group } 1 \text{ and three in group } 2)\) had mutations that made them ineligible for treatment with cabotegravir/rilpivirine: E138A/K \((n = 4)\), K101P/E/Q \((n = 4)\), and Y181C \((n = 1)\) (Table 2).
Table 2. Comparative data for the retrospective study.

| Retrospective Section          | Dx before Age 10 (n = 66) |   | Dx between 10 and 25 (n = 62) |   |
|-------------------------------|----------------------------|---|-------------------------------|---|
| Treatment adherence (according to the medical file) | N     | %   | N     | %   |
| Optimal                       | 25    | 37.9% | 26    | 41.9% |
| Good                          | 30    | 45.5% | 30    | 48.4% |
| Poor, inadequate              | 11    | 16.7% | 6     | 9.7%  |
| Immunovirological efficacy    | N     |       | N     |       |
| Good immunological and virological efficacy | 52    | 78.8% | 58    | 93.5% |
| Good immunological but poor virological efficacy | 6     | 9.1%  | 4     | 6.5%  |
| Poor virological but poor immunological efficacy | 2     | 3.0%  | 0     | 0.0%  |
| Poor immunological and virological efficacy | 6     | 9.1%  | 0     | 0.0%  |
| Resistance in each class of antiretroviral | N     |       | N     |       |
| NRTI resistance               | 23/48 | 47.9% | 1/40  | 2.5%  |
| NNRTI resistance (excluding RPV) | 19/48 | 39.6% | 11/40 | 27.5% |
| PI resistance                 | 10/48 | 20.8% | 2/40  | 5.0%  |
| INSTI resistance              | 4/21  | 19.0% | 1/20  | 5.0%  |
| RPV resistance                | 10/53 | 18.9% | 6/40  | 15.0% |
| Eligibility for CAB/RPV LA    | 53    | 80.3% | 56    | 90.3% |

Dx: Diagnosed; NRTI: Nucleoside Reverse Transcriptase Inhibitor; NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor; PI: Protease Inhibitor; INSTI: Integrase Strand Transfer Inhibitor; RPV: Rilpivirine. 1 Reverse transcriptase resistance mutations (excluding RPV) M184V (23:0), K103T/N/S/R (14:4), T215Y/D/L/C/F (12:0), M41L (8:0), V179I/D/E/T (6:3), K219E/R/Q (5:0), K70E/T/R (4:1), T69N/D/A (4:0), L74I (4:0), V106I/M (3:3), P225H (3:1), N348I (2:2), P227L (2:1), G190A (2:1), V75I/T (2:0). 2 PI resistance mutations M36I/L (24:3), L63A/P/S/M/V (16:4), K20I/R/T/M (13:4), I13V (11:4), L89M (10:3), L10I/F/V/R (10:3), V82I/L/A/F (8:0), I54M/L/V (6:1), I93L (6:1), L33F/V (6:0), L90M (5:1), I47V (3:0), V32I (2:0), Q58E (2:0). 3 INSTI resistance mutations N155H (2:0), V151I (1:0), L74I (0:2), M50I (0:1). 4 RPV resistance mutations E138A/K (2:2), K101P/E/Q (3:1), Y181C (1:0). (x:y) x is the number of patients carrying this mutation in group 1: y is the number of patients carrying this mutation in group 2.

3.2. Cross-Sectional Study

Four patients were excluded from the cross-sectional study because they were already receiving a long-acting injectable antiretroviral combination. In group 1, out of the 65 who received the questionnaire, 16 people responded (25%). In group 2, out of the 59 who received the questionnaire, 15 people responded (25%).

We did not find a statistically significant association between group and treatment adherence considering the mean number of missed pills over 2 days (0.25 (95% CI: 0–0.61) vs. 0.11 (0–0.33); p = 0.95), and the mean number of missed pills over 7 days (0.56 (95% CI: 0–1.18) vs. 0.20 (0–0.43); p = 0.57). There was, however, a significant difference between adherence noted in their files and self-reported adherence, since only 45% of the patients reported the same level of adherence as that assessed by a health professional (prescribing physician, clinical pharmacist, or clinical nurse).

Among patients with “optimal” chart adherence, 72% self-rated their adherence as such. Noticeably, all patients whose adherence was judged to be “poor or insufficient” considered their adherence to be “optimal” and reported no omissions over 7 days. Eleven patients considered their adherence to be optimal, although it was described as imperfect or insufficient by health professionals. Conversely, five patients considered that their
treatment compliance was not optimal, while the healthcare professional considered it as optimal.

The patients included in group 1 generally reported more social activities, and among them, two said that these situations interfered with taking their antiretroviral treatment properly. Compared to three patients in group 2, five patients in group 1 reported that ART negatively impacted their quality of life. In both groups, the main self-reported cause of non-adherence was simple forgetfulness (59%). Patients also mentioned interference with social life (12%), lack of time to take the medication (10%), and the fear of a possible disclosure of their HIV-positive status (10%) as being etiologies of non-adherence. The semi-structured questionnaire identified additional causes of non-adherence as forgetting renewal at the pharmacy \( (n = 1) \), going outside the home without bringing along the pills (4%), and “Taking a daily treatment for a pathology imposed since birth” (mentioned by one patient). Another patient reported the size of the pills as an obstacle to adherence.

Regarding interest in long-acting ART, patients in group 2 were more likely (73.3%) to be interested in the injectable cabotegravir/rilpivirine combination than patients in group 1 (56.3%), but this difference was not significant \( (p = 0.32) \) (Table 3).

Table 3. Comparative data for the cross-sectional study.

| Comparison                        | Dx before Age 10 \( (n = 16) \) | Dx between 10 and 25 \( (n = 15) \) |
|-----------------------------------|-----------------------------------|-------------------------------------|
| Number of missed pills over 2 days | 0.25 \( 0–0.61 \)                | 0.13 \( 0–0.33 \)                   |
| Number of missed pills over 7 days | 0.56 \( 0–1.18 \)                | 0.20 \( 0–0.43 \)                   |
| Self-rated importance of antiretroviral treatment | 9.67 \( 9.17–10.16 \) | 9.53 \( 8.95–10.12 \) |
| Perception of treatment as essential for health | 15 \( 93.8\% \) | 14 \( 93.3\% \) |
| Interference between social activities and adherence to antiretrovirals | 2 \( 12.5\% \) | 0 \( 0.0\% \) |
| Negative impact on quality of life | 5 \( 31.3\% \) | 3 \( 20.0\% \) |
| Interest in long-acting injectable antiretroviral treatment | 9 \( 56.3\% \) | 11 \( 73.3\% \) |

Dx, Diagnosed; 95% CI, 95% Confidence Interval.

4. Discussion

Our study has found an association between adherence and immune-virological efficacy. The relation between adherence and virological efficacy is well established in the literature \[4,6,13\]. Our data do not support the assumption that adherence is different depending on the age of seroconversion. Similarly, Vanthournout et al. \[4\] did not find a significant association between ART adherence, history of treatment failure, the clinical stage of the pathology, age at diagnosis disclosure, and the duration of taking ART. However, fewer patients with perinatally acquired HIV achieved immunological and virological controls, and their virus showed more resistance mutations, as expected considering the difference between the presumed mean duration of infection in the two groups. Consequently, ART regimens were significantly more complex in this group.

Clinicians see the new injectable therapies as an attractive option for improving adherence, particularly among the younger population, who often do not take other medications. Indeed, 65% of those surveyed expressed interest. However, compared with those who had acquired HIV later, there was a trend toward lower eligibility among those with perinatally acquired HIV, as their virus had more accumulated mutations. This is not surprising, as they had both longer exposure to antiretrovirals and exposure to older agents.

Adolescents and young adults living with HIV are exposed to periods of great change, particularly through puberty. Thus, it is necessary to consider the barriers to adherence
related to developmental factors: physical, cognitive, social, emotional changes, combined with an emerging recognition of their sexual identity [8]. These barriers to adherence include in particular motivational barriers related to the acceptance of the disease, and factors related to the impact of potential stigmatization [8]. Social barriers to compliance are favored by chaotic and unstructured lifestyles (disorganization, drug addiction, etc.), material constraints, or even a lack of support from the patient’s social environment (family and friends) [9]. In our study, more than half the respondents reported a negative impact of their antiretrovirals on their quality of life.

This study is not without limitations, especially with regard to the survey component. The 25% response rate to the questionnaire may have affected representativeness. Our study may have a response bias. For example, people who are more involved in their healthcare or with a less busy schedule may be more likely to respond. Potential participants were contacted multiple times, and, in our opinion, more solicitation would not have been acceptable. We do not believe that a written questionnaire would have improved the response rate, as our study population was under 30 years of age. Moreover, it would have posed greater confidentiality issues. In addition, in both groups, on average, higher ART adherence was noted when it was self-assessed using the online questionnaire, compared to adherence according to the notes in the medical file, probably showing a social desirability bias. Finally, due to the small sample, our study might have been underpowered to detect small differences between groups.

In conclusion, we did not find a difference in antiretroviral adherence between patients who acquired HIV in childhood vs. those who acquired it in adolescence/early adulthood. Regardless of the transmission mode, young people living with HIV need appropriate support and methods to reduce various adherence barriers, and to maximize their chances of obtaining a long-term undetectable viral load. Even though many young patients may be interested in long-acting injectable antivirals, it is important to look at previous genotypes to ensure eligibility.

Author Contributions: Conceptualization, methodology, and formal analysis, V.M.-L., A.M. and S.M.; investigation, A.M. and A.-G.G.; writing—original draft preparation, A.M.; writing—review and editing, V.M.-L., S.M., A.-G.G. and B.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and received multicentric approval by the Institutional Ethics Committee CHUM (protocol code MP-02-2021-9840 on 9 April 2021.

Informed Consent Statement: Informed consent was obtained from all subjects who answered the electronic questionnaire.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to thank Adriana Rodriguez from the MUHC for her help in setting up the cross-sectional part of our study. The authors would also like to thank the participants who agreed to respond to the semi-structured questionnaire.

Conflicts of Interest: Anthony Marcellin, Suzanne Marcotte, and Anne-Geneviève Genest declare no conflict of interest. Valérie Martel-Laferrière is supported by the program Clinical Research Scholars—Junior 1 of FRQS and has received consultant honoraria from Gilead and Abbvie and research grants from Gilead and Merck. Bertrand Lebouché reports grants for investigator-initiated studies from Viiv Healthcare, Merck, and Gilead and consulting fees from Viiv Healthcare, Merck, and Gilead. BL is the holder of a Canadian Institutes for Health Research, Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical Trials for HIV Care and is also supported by a career award, LE 250, from the Quebec’s Ministry of Health for researchers in Family Medicine.
Appendix A. Complete Questionnaire

INSTRUCTIONS FOR FILLING OUT THE QUESTIONNAIRE

Like most people, it is likely that you have missed taking one or several pills at some point in time. In fact, even the most disciplined people may not always take all of their medication as they would wish to because of forgetfulness, unexpected situations, etc. The most difficult thing will no doubt be for you to remember the times that you have missed taking one or several pills. It is thus important for you to make an effort to remember so that your answers are as precise as possible. Take the time you need to answer. We ask you to answer the questionnaire with only your ANTIRETROVIRAL medication in mind. The word “pill” is used to designate tablets, caplets, capsules. The expression “miss one or several pills” means NOT taking all your antiretroviral pills at a certain time. Answer all the questions by entering a number or by checking one of the suggested boxes.

Thank you for your precious collaboration.

Age on May 1st 2021: _________
Gender:
- man
- woman
- other or I prefer not to answer this question

At what age did you acquire HIV?
- Under the age of 10
- Between the ages of 10 to 25

Transmission mode:
- I have had the virus since childhood
- Sexual practices
- Drug use
- Blood transfusion or other medical procedure
- Other/Unknown
- I prefer not to answer this question

1. Indicate the name of the antiretroviral medications you take. Next, enter the number of pills that you must take each day for each of these medications. (please refer to the chart provided).

| Name of Antiretroviral Medication * | Number of Antiretroviral Pills |
|-------------------------------------|-------------------------------|
|                                     | Wake-Up/Breakfast/Morning | Lunch/Afternoon | Supper/Evening/Bedtime |
| Example: Lamivudine (Epivir®) * | 1 | 1 |

* Indicate one of the names for these medications.

2. How many antiretroviral pills have you missed during the last 2 days? (if you haven’t missed any, write down the number « 0 »). If you are not taking an antiretroviral pill at this time of day, leave a blank in the appropriate box.
### Number of antiretroviral pills that you missed...

|                                 | Wake-up/Breakfast/Morning | Lunch/Afternoon | Supper/Evening/Bedtime |
|---------------------------------|---------------------------|-----------------|------------------------|
| Example:                        |                           |                 |                        |
| Yesterday                       |                           |                 |                        |
| Day before yesterday            |                           |                 |                        |

#### 3. During the last 7 days, did you...

| YES | NO |
|-----|----|
|     |    |
|     |    |
|     |    |
|     |    |
|     |    |
|     |    |
|     |    |

- Go out for a leisure activity? (movie, show, physical activity, etc.)?
- Go to a restaurant?
- Go to a bar?
- Go to a party?
- Sleep away from home?
- Visit friend(s) or family member(s)?
- Receive a visit from friend(s) or family member(s)?
- Attend a meeting

#### 4. During the last 7 days, did one of the situations listed in Question 3 prevent you from taking all your antiretroviral pills?

- [ ] YES
- [ ] NO

#### 5. During the last 7 days, how many times in total, did you miss taking one or more of your antiretroviral pills? (If you haven’t missed any, write down the number « 0 »)

**TIMES**

- [ ] Q5b. In total, this represents how many antiretroviral pills?

#### 6. Do you think your antiretroviral treatment is essential for your health?

- [ ] Yes
- [ ] No

#### 7. On a scale of 1 to 10, how would you rate the importance of taking your antiretroviral treatment?

1 2 3 4 5 6 7 8 9 10

#### 8. Do you think that taking your antiretroviral treatment has a negative impact on your quality of life?

- [ ] No
- [ ] Yes
  - [ ] Small consequences
  - [ ] Big consequences

#### 9. Like most people, it is likely that you have missed taking one or several pills at some point in time. When this happens to you, what is the reason? *(many answers possible)*

- [ ] I don’t think I need it
- [ ] Treatment interferes with my social life
- [ ] I’m afraid that people will find out I have HIV
☐ I find that it doesn’t help me and that I don’t feel better with it
☐ I don’t have time to take it
☐ I forgot to take it
☐ I don’t take it for financial reasons
☐ I only take it when I feel bad
☐ I only take it when I feel good

10. Are there any other reasons why you are not taking your treatment as prescribed?

*Long-acting antiretroviral treatments are now available: the medication should be monthly or every two months by a nurse, an injection in each buttock.*

☐ Yes
☐ No

11. If this treatment was possible for you, would you like to switch from a treatment taken by mouth to an injected treatment because it does not need to be taken every day?

☐ Yes
☐ No

12. If not, for which reason(s)?

13. Do you think this treatment would improve your treatment adherence? (Treatment adherence = when you take the medicine correctly, as prescribed by your doctor) *(many answers possible)*

☐ Yes
☐ No, my compliance is already optimal
☐ No, because of the constraint of a monthly or every two months appointment
☐ No, because I’m afraid of the pain caused by the injection
☐ Other, please specify

Reference question 1 to 5: Godin, G., Gagné, C., Naccache, H. Validation of a self-reported questionnaire assessing adherence to antiretroviral medication. AIDS Patient Care 2003, 17, 325–332.

References
1. Reisner, S.L.; Mimiaga, M.J.; Skeer, M.; Perkovich, B.; Johnson, C.V.; Safren, S.A. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. *Top HIV Med.* 2009, 17, 14–25. [PubMed]
2. Engler, K.; Lénart, A.; Lessard, D.; Toupin, I.; Lebouché, B. Barriers to antiretroviral therapy adherence in developed countries: A qualitative synthesis to develop a conceptual framework for a new patient-reported outcome measure. *AIDS Care* 2018, 30, 17–28. [CrossRef] [PubMed]
3. Vreeman, R.C.; Wiehe, S.E.; Pearce, E.C.; Nyandiko, W.M. A Systematic Review of Pediatric Adherence to Antiretroviral Therapy in Low- and Middle-Income Countries. *Pediatric Infect. Dis. J.* 2008, 27, 686–691. [CrossRef] [PubMed]
4. Vanhournout, B.; Van Der Kelen, E.; Elate, D.; Goetghoub, T.; Hainaut, M.; Levy, J. Clinical evaluation of adherence to antiretroviral therapy in adolescents infected by HIV since infancy. *Arch. Pédiatric* 2013, 20, 348–355. [CrossRef] [PubMed]
5. Haberer, J.; Mellins, C. Pediatric adherence to HIV antiretroviral therapy. *Curr. HIV/AIDS Rep.* 2009, 6, 194–200. [CrossRef] [PubMed]
6. Bezabhe, W.M.; Chalmers, L.; Berezni, L.R.; Peterson, G.M. Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-Analysis. *Medicine* 2016, 95, e3361. [CrossRef] [PubMed]
7. Kim, S.-H.; Gerver, S.M.; Fidler, S.; Ward, H. Adherence to antiretroviral therapy in adolescents living with HIV: Systematic review and meta-analysis. *AIDS* 2014, 28, 1945–1956. [CrossRef] [PubMed]
8. Rotheram-Borus, M.J.; Flannery, D.; Rice, E.; Lester, P. Families living with HIV. *AIDS Care* 2005, 17, 978–987. [CrossRef] [PubMed]
9. Stanford University. HIV Drug Resistance Database. Available online: https://hivdb.stanford.edu/ (accessed on 1 June 2022).
10. International Antiviral Society USA. HIV Drug Resistance Mutations. Available online: https://www.iasusa.org/resources/hiv-drug-resistance-mutations/ (accessed on 1 June 2022).
11. Godin, G.; Gagné, C.; Naccache, H. Validation of a self-reported questionnaire assessing adherence to antiretroviral medication. *AIDS Patient Care STDS* 2003, 17, 325–332. [CrossRef] [PubMed]
12. Williams, P.L.; Storm, D.; Montepiedra, G.; Nichols, S.; Kammerer, B.; Sirois, P.A.; Farley, J.; Malee, K.; PACTG 219C Team. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. *Pediatrics* 2006, 118, e1745–e1757. [CrossRef] [PubMed]